Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.
Anaptysbio’s etokimab needs to beat Dupixent, while Retrophin takes aims at an underserved rare disease.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
The number of late-stage assets in the hands of the industry’s behemoths is shrinking, and this can only put more pressure on companies to do deals.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.